Article
Afatinib treatment in a large real-world cohort of nonsmall cell lung cancer patients with common and uncommon epidermal growth factor receptor mutation.
International journal of cancer - 15 Feb 2022
Huang Chi-Hsien, Ju Jia-Shiuan, Chiu Tzu-Hsuan, Huang Allen Chung-Cheng, Tung Pi-Hung, Wang Chin-Chou, Liu Chien-Ying, Chung Fu-Tsai, Fang Yueh-Fu, Guo Yi-Ke, Kuo Chih-Hsi Scott, Yang Cheng-Ta
Abstract excerpt
The epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) afatinib improves survival in nonsmall cell lung cancer (NSCLC) patients with EGFR mutation. We analysed the outcome between EGFR mutation subtypes in a large afatinib-treated cohort in which 516 EGFR-mutated NSCLC patients receiving afatinib as front-line treatment. EGFR uncommon mutations include exon 20 insertion, de novo T790M of high...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.